Special Issue

Thermal Ablation in the Management for Colorectal Liver Metastases

Message from the Guest Editors

Targeted minimally invasive, image-guided therapies in the management of colorectal liver metastases (CRLMs) play an increasingly important role in clinical oncology and health care. These rapidly evolving treatment modalities (e.g., microwave ablation, irreversible electroporation or stereotactic body radiation therapy) are characterized by the local delivery of (non-)thermal energy or radiation at a high dosage, directly affecting the tumor tissue in order to treat cancer more effectively. The increasing role of minimally invasive, real-time, image-guided and/or navigated treatment techniques for CRLM is the primary topic of this Special Issue. We aim to procure high-quality original research and review articles that address the available kinds of (non-)thermal and radiation-related treatment options for CRLM in order to improve oncological outcomes in interventional and radiation oncology. Reports of studies highlighting the use of real-time image guiding or navigation tools or ablation confirmation techniques for volumetric assessment of the ablation zone are particularly welcome.

Guest Editors

Prof. Dr. Martijn Meijerink
Department of Radiology, Amsterdam UMC, Amsterdam, The Netherlands

Dr. Robbert S. Puijk
Department of Radiology, Amsterdam UMC, Amsterdam, The Netherlands

Deadline for manuscript submissions

closed (20 March 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/130904

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)